Aptose Biosciences Q3 2023 Earnings Report $0.21 -0.01 (-4.04%) As of 04:00 PM Eastern Earnings HistoryForecast Aptose Biosciences EPS ResultsActual EPS-$1.76Consensus EPS -$2.16Beat/MissBeat by +$0.40One Year Ago EPSN/AAptose Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAptose Biosciences Announcement DetailsQuarterQ3 2023Date11/9/2023TimeN/AConference Call ResourcesAPTO Earnings History Aptose Biosciences Earnings HeadlinesAptose Biosciences Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement - Special Shareholders' Meeting Scheduled for January 27January 22 at 4:09 AM | americanbankingnews.comAptose Biosciences faces Nasdaq delisting over share priceJanuary 21 at 10:36 PM | msn.comDonald Trump is about to free crypto from its chains …With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only set to be released from its constraints … it could be about to explode. Trump has vowed to roll back Biden’s “crusade against crypto” on his first day in office.January 22, 2025 | Weiss Ratings (Ad)Aptose Biosciences Inc. Files 8-K ReportJanuary 21 at 2:05 AM | americanbankingnews.comAptose Biosciences Inc APSJanuary 16, 2025 | morningstar.comAptose Biosciences (NASDAQ:APTO) Now Covered by StockNews.comJanuary 16, 2025 | americanbankingnews.comSee More Aptose Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aptose Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aptose Biosciences and other key companies, straight to your email. Email Address About Aptose BiosciencesAptose Biosciences (NASDAQ:APTO), a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.View Aptose Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings CSX (1/23/2025)Intel (1/23/2025)Texas Instruments (1/23/2025)Elevance Health (1/23/2025)Freeport-McMoRan (1/23/2025)General Electric (1/23/2025)Union Pacific (1/23/2025)American Express (1/24/2025)HCA Healthcare (1/24/2025)NextEra Energy (1/24/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
